FDA Expands Use of Untested
H1N1 Vaccines to Infants and Children
The U.S. Food and Drug Administration has extended its sadistic
badge of approval on untested CSL Ltd H1N1 influenza vaccines
to include children ages 6 months and older. This vaccine was
previously approved only for use in adults, ages 18 years and
older.
The companys 2009 H1N1 vaccine was approved based on the
same unfounded and irresponsible testing protocols that have taken
the drug industry by storm in the face of speedy approvals to
rush pandemic vaccinations worldwide.
Firstly, the National Institute for Allergies and Infectious Disease
conducted a study which showed that 75%
of children under 35 months of age received absolutely no
protection from the H1N1 vaccine. In addition 64%
of children between 3 to 9 years old received no protection
from the vaccine.
It should also be noted that the standard to test any vaccine
is to first produce exposure to the virus and subsequently prevent
the infection. This is the only scientifically established method
of concluding the efficacy of any vaccine. No H1N1 vaccine
has ever been tested using this protocol and all H1N1 vaccines
have therefore been approved using scientific fraud!
CSL's
PANVAX Vaccine contains immunotoxins, neurotoxins and carcinogens
including beta-propiolactone
(carcinogen), neomycin
(immunotoxin), sodium
taurodeoxycholate (carcinogen/immunotoxin), polymyxin
(neurotoxin) and thimerosal
(neurotoxin).
See Report - The
Goal of Every H1N1 Swine Flu Vaccine
The CSL's
Afluria H1N1 Influenza Vaccine contains almost identical concentrations
of these toxins.
An ongoing
study by CSL's 2009 H1N1 Influenza Vaccine in Healthy Children
is still ongoing with no conclusive results.
Another study on CSL's
2009 H1N1 Influenza Vaccine in healthy pediatric US populations
is also ongoing with no conclusive results.
There is also a trial (still
not open for participant recruitment) on the CSL H1N1 Influenza
Vaccine with and without AS03 adjuvant, which has again offered
no conclusive results.
The approval for the H1N1 vaccine being extended to children
was not based on any H1N1 vaccine trial but on a study of CSL's
seasonal flu vaccine in children. The FDA is using these findings
to justify inoculating children across America with the H1N1 vaccine,
a criminal behavior at the highest levels of medical science.
Common adverse events experienced by children after administration
of seasonal and H1N1 vaccines typically include , pain, redness,
swelling, fatigue, headaches, arthralgia (joint inflammation),
myalgia (muscle inflammation), shivering, sweating, swollen lymph
nodes, fever, vomiting, tingling or numbness of the hands or feet,
shortness of breath, vasculitis (inflammation of the blood vessels).
As with any medical product, serious adverse events may occur
such as blood and lymphatic system disorders (lymphadenopathy),
psychiatric disorders (insomnia), nervous system disorders (dizziness,
paraesthesia, inflammation of the central nervous system, inflammation
of nerves, autoimmune disorders affecting myelin sheaths of nerves
such as Guillain-Barré Syndrome), ear and labyrinth disorders
(vertigo), respiratory, thoracic and mediastinal disorders (dyspnoea),
gastrointestinal disorders (nausea, diarrhea, abdominal pain,
vomiting, dyspepsia, stomach discomfort), skin and subcutaneous
tissue disorders (pruritus, rash), musculoskeletal and connective
tissue disorders (back pain, musculoskeletal stiffness, neck pain,
muscle spasms, pain in extremity), general disorders and administration
site conditions (bruising, asthenia, chest pain, malaise).
The FDA says it is collaborating with the U.S. Department of
Health and Human Services, including the Centers for Disease Control
and Prevention, and other government agencies to enhance the capacity
for adverse event safety monitoring during and after the 2009
H1N1 vaccination program, which could tally into tens of thousands
if not more.
Ironically, CSL Ltd states that the vaccines are preservative-free
even though they contain thimerosal,
a mercury derivative which is a neurotoxin and potentially lethal
preservative.
Both vaccines approved are manufactured by CSL Ltd. of Australia.
Dave Mihalovic is a Naturopathic Doctor who specializes in
vaccine research, cancer prevention and a natural approach to
treatment.
Reference Source FDA.gov
November 13, 2009
...............................................................................................................
|